Latest News About Vigil

I don’t have live access to up-to-the-minute feeds right now, but I can share the latest widely reported developments on Vigil Neuroscience based on recent public coverage.

• Vigil Neuroscience (VIGL) has been in the news due to its TREM2 agonist programs, particularly VG-3927 for Alzheimer’s disease and iluzanebart for ALSP. Reports in mid-2024 through 2025 highlighted interim data, progresses through early trials, and regulatory discussions. [cite ][cite ]
• There were major corporate developments in 2024–2025 involving a strategic investment from Sanofi and a definitive merger agreement that would make Vigil a subsidiary of Sanofi, with focus on accelerating the TREM2 pipeline. Shareholder actions and regulatory clearances were noted as prerequisites. [cite ][cite ]
• In quarterly updates, Vigil disclosed updates on clinical programs, trial milestones, and potential avenues for accelerated approval considerations for iluzanebart in ALSP, along with ongoing enrollment and data readouts for VG-3927. [cite ]

If you’d like, I can:

• Narrow to the most recent week or month and summarize specific headlines.
• Pull exact press releases and provide a timeline of key events.
• Create a quick snapshot (bullets or a tiny chart) of program milestones and regulatory status.

Would you prefer a focused summary of the very latest headlines, or a sourced timeline of Vigil’s major corporate and clinical milestones?